Title:Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases
Volume: 11
Issue: 1
Author(s): Zhen-He Wang, Benjamin B. Davis, De-Qian Jiang, Ting-Ting Zhao and Dan-Yan Xu
Affiliation:
Keywords:
Soluble epoxide hydrolase, epoxyeicosatrienoic acids, cardiovascular diseases, fibrinolysis, stabilizing EETs, peroxisomes
Abstract: Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by
reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated
through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances
the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases.
Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs
strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemiareperfusion
injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release
bradykinin via an EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. Summary: Inhibition of
sEH has been shown to improve several aspects of cardiovascular diseases, including inflammation, hypertension, cardiac
hypertrophy and atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the treatment of cardiovascular
diseases.
